These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29448072)

  • 1. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
    Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
    Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
    J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
    Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
    Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.
    Pivot X; Cortés J; Lüftner D; Lyman GH; Curigliano G; Bondarenko IM; Ahn JH; Im SA; Litwiniuk M; Shparyk YV; Ho GF; Kislov NV; Wojtukiewicz M; Sarosiek T; Chae YS; Ahn JS; Jang H; Kim S; Lee J; Yoon Y
    JAMA Netw Open; 2023 Apr; 6(4):e235822. PubMed ID: 37022687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
    Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
    Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
    Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Jackisch C; Hegg R; Stroyakovskiy D; Ahn JS; Melichar B; Chen SC; Kim SB; Lichinitser M; Starosławska E; Kunz G; Falcon S; Chen ST; Crepelle-Fléchais A; Heinzmann D; Shing M; Pivot X
    Eur J Cancer; 2016 Jul; 62():62-75. PubMed ID: 27208905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
    Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.
    Zuo W; Wang Z; Qian J; Ma X; Niu Z; Ou J; Mo Q; Sun J; Li X; Wang Q; Yao Y; Yu G; Li H; Chen D; Zhang H; Geng C; Qiao G; Zhao M; Zhang B; Kang X; Zhang J; Shao Z
    Br J Cancer; 2024 Sep; 131(4):668-675. PubMed ID: 38906970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
    Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
    Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.